|
Exhibit 99.1
SANGAMO BIOSCIENCES ANNOUNCES RESEARCH COLLABORATION AGREEMENT
WITH PFIZER INC
ZFP TECHNOLOGY TO BE USED TO ENHANCE PROTEIN PHARMACEUTICAL
PRODUCTION
RICHMOND, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Sangamo
BioSciences, Inc.
(Nasdaq: SGMO) announced today that it had entered into a
research collaboration
with Pfizer Inc in the field of enhanced protein production.
Under the terms of
the agreement, Pfizer will fund research at Sangamo and Sangamo
will provide its
proprietary zinc finger DNA binding protein (ZFP) technology for
Pfizer to
assess its feasibility for use in mammalian cell- based protein
pharmaceutical
production. Sangamo will generate novel cell lines and vector
systems for
enhanced protein production as well as novel technology for
rapid and robust
creation of new production cell lines. The financial terms of
the agreement were
not disclosed.
"We are very pleased to be able to provide Pfizer, the world's
leading
research-based pharmaceutical company, with our ZFP gene
activation technology,"
said Edward Lanphier, Sangamo's president and chief executive
officer. "ZFP
transcription factors are used to regulate genes expressing
protein
pharmaceuticals and we can engineer zinc finger nucleases (ZFNs)
to facilitate
the efficient generation of production cell lines with altered
traits."
Zinc finger DNA-binding proteins (ZFPs) are the dominant class
of naturally
occurring transcription factors in organisms from yeast to
humans. Transcription
factors, which are found in the nucleus of every cell, bind to
DNA to regulate
gene expression. Though there are many kinds of transcription
factors, only zinc
finger
| 
